Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.

Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, Sreenivas V, Singh S.

Clin Infect Dis. 2010 Mar 15;50(6):833-9. doi: 10.1086/650576.

PMID:
20156055
2.

[Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].

Kaneko Y, Nagayama N, Kawabe Y, Shimada M, Suzuki J, Kunogi M, Matsui Y, Kawashima M, Suzuki J, Ariga H, Oshima N, Masuda K, Matsui H, Nagai H, Tamura A, Akagawa S, Toyoda E, Machida K, Kurashima A, Yotsumoto H.

Kekkaku. 2008 Jan;83(1):13-9. Japanese.

PMID:
18283910
3.

Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.

Jeong I, Park JS, Cho YJ, Yoon HI, Song J, Lee CT, Lee JH.

J Korean Med Sci. 2015 Feb;30(2):167-72. doi: 10.3346/jkms.2015.30.2.167. Epub 2015 Jan 21.

4.

Antituberculosis drugs and hepatotoxicity.

Yew WW, Leung CC.

Respirology. 2006 Nov;11(6):699-707. Review.

PMID:
17052297
6.

[Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].

Nagayama N, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H, Mohri M.

Kekkaku. 2003 Apr;78(4):339-46. Japanese.

PMID:
12739393
7.

Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?

Nader LA, de Mattos AA, Picon PD, Bassanesi SL, De Mattos AZ, Pineiro Rodriguez M.

Ann Hepatol. 2010 Jan-Mar;9(1):70-4.

PMID:
20308724
8.

First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.

Bouazzi OE, Hammi S, Bourkadi JE, Tebaa A, Tanani DS, Soulaymani-Bencheikh R, Badrane N, Bengueddour R.

Pan Afr Med J. 2016 Nov 16;25:167. doi: 10.11604/pamj.2016.25.167.10060. eCollection 2016.

9.

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.

Lin HS, Cheng CW, Lin MS, Chou YL, Chang PJ, Lin JC, Ye JJ.

Clin Interv Aging. 2016 Mar 11;11:299-306. doi: 10.2147/CIA.S95411. eCollection 2016.

10.

Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.

Satyaraddi A, Velpandian T, Sharma SK, Vishnubhatla S, Sharma A, Sirohiwal A, Makharia GK, Sinha S, Biswas A, Singh S.

Int J Tuberc Lung Dis. 2014 Feb;18(2):188-95, i-iii. doi: 10.5588/ijtld.13.0128.

PMID:
24429311
11.

Hepatotoxicity of pyrazinamide: cohort and case-control analyses.

Chang KC, Leung CC, Yew WW, Lau TY, Tam CM.

Am J Respir Crit Care Med. 2008 Jun 15;177(12):1391-6. doi: 10.1164/rccm.200802-355OC. Epub 2008 Apr 3.

PMID:
18388355
12.

Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens.

Shamaei M, Mirsaeidi M, Baghaei P, Mosaei H, Marjani M, Tabarsi P.

Am J Ther. 2017 Mar/Apr;24(2):e144-e149. doi: 10.1097/MJT.0000000000000218.

PMID:
26057141
13.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators.

Ann Intern Med. 2002 Oct 15;137(8):640-7.

PMID:
12379063
14.

Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.

Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R.

J Gastroenterol Hepatol. 2008 Feb;23(2):192-202. Epub 2007 Nov 6. Review.

PMID:
17995946
15.

Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.

Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ.

Chest. 2005 Apr;127(4):1304-11.

PMID:
15821209
16.
18.

Management of and risk factors related to hepatotoxicity during tuberculosis treatment.

Babalık A, Arda H, Bakırcı N, Ağca S, Oruç K, Kızıltaş S, Cetintaş G, Calışır HC.

Tuberk Toraks. 2012;60(2):136-44.

19.

[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].

Camacho A, Pérez-Camacho I, Rivero A, Natera C, García-Lázaro M, Castón JJ, Gallo M, Kindelán JM, Torre-Cisneros J.

Enferm Infecc Microbiol Clin. 2010 Apr;28(4):239-44. doi: 10.1016/j.eimc.2009.04.003. Epub 2009 Aug 3. Spanish.

PMID:
19647900
20.

Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.

Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, Kim SJ, Jindani A, Enarson DA, Nunn AJ; Study C Trial Group.

JAMA. 2011 Apr 13;305(14):1415-23. doi: 10.1001/jama.2011.436. Erratum in: JAMA. 2011 Sep 28;306(12):1327.

PMID:
21486974

Supplemental Content

Support Center